Thyroid cancer drug under Long-Term safety watch
NCT ID NCT02185560
First seen Mar 10, 2026 · Last updated May 23, 2026 · Updated 11 times
Summary
This study looks at the safety and effectiveness of the drug sorafenib (Nexavar) in people with a type of advanced thyroid cancer that cannot be removed by surgery. Over 450 participants are being followed for up to 2 years to track side effects, how long they stay on the drug, and survival. The goal is to better understand the real-world risks and benefits of this treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYROID CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Study site
Multiple Locations, Japan
Conditions
Explore the condition pages connected to this study.